

# Effect of Doxorubicin on Cardiac Myocytes: Role of Apoptosis, Autophagy and other Proteolytic Pathways

Wilhelm P Mistiaen<sup>1,2,\*</sup>

<sup>1</sup>University of Antwerp, Faculty of Medicine and Health Sciences, Universiteitsplein 1, 2020 Antwerp, Belgium

<sup>2</sup>Artesis-Plantijn University College Antwerp, Noorderplaats 2, 2000 Antwerp, Belgium

**Abstract:** Doxorubicin is a very effective chemotherapeutic agent. However, its use is limited by serious cardiac side effects, including long-term irreversible cardiac failure which is often fatal. These effects are related to the cumulative dose but other factors also play a role. Through a systematic search in an electronic database, manuscripts dealing with this matter were included. Exposure of the heart to doxorubicin results in three types of stress: 1] genotoxic, 2] energetic and 3] oxidative stress. These effects are closely related with the dependence of the heart on oxidative phosphorylation, its low defenses against reactive oxygen species and with the peculiarities of mitochondria, which are abundantly present in cardiac tissue. In most manuscripts, the cellular effects of doxorubicin are documented by changes in enzymatic pathways within cardiomyocytes. These pathways have mutual influences, which complicate the interpretation of results. These pathways often result in proteolysis, cellular damage and apoptotic cell death. Necrosis and autophagy are also involved as mechanisms. Most of the included manuscripts deal with in-vitro experiments with anti-oxidant agents, using cardiomyoblasts and H9c2 cell lines as well as in-vivo short-term murine models. However, long-term animal models are lacking. Clinical articles and experiments with cells other than cardiomyocytes are few. The effects of doxorubicin on the extracellular matrix also needs further exploration. These areas need further exploration.

**Keywords:** Doxorubicin, Reactive oxygen species, Genotoxic stress, Energetic stress, Apoptosis, autophagy, Mitochondria.

## INTRODUCTION

Doxorubicin has been introduced from 1960's [1] as an effective treatment against several types of cancer. These "cell-cycle non-specific agents" are derived from Streptomyces bacteria [2] and are very effective. Its use, however, is limited by their short and long-term cardio-toxic effect which ranges from asymptomatic cardiac changes such as lower left ventricular [LV] mass, diastolic and systolic dysfunction, abnormal regional wall contractility to cardiomyopathy, overt heart failure and even cardiogenic shock [3-7]. There is an acute, an early onset and a late onset doxorubicin toxicity [1, 8]. The acute toxicity manifests itself as hypotension, tachycardia and arrhythmias [9]. It appears immediately after treatment and disappears after the discontinuation of the treatment. In 1973, a high lethality of CHF was observed. This was refractory to every treatment available at that time. A maximal dose of 550 mg/m<sup>2</sup> was proposed to avoid such calamities. This event could be reversible [1]. The early-onset cardiotoxicity can appear in the first year after treatment with doxorubicin; it presents itself as chronic dilated CMP. The late-onset cardiotoxicity develops after a period of seemingly normal LVF, with a latency period which can last several years.

Echocardiographic abnormalities have been found in 65% of the patients [1]. LV dysfunction evolves to an irreversible CHF, with arrhythmias and fibrosis. This is clinically most relevant [9]. Cumulative dose, irradiation and length of follow-up had a significant effect [10]. These events can be dose dependent, cumulative and irreversible [11]. Its mechanisms are poorly understood. In an old retrospective series, prevalence of clinical heart failure was 2% with a mortality of 71% [12]. LV dysfunction at 10 years was detected in 18% in patients who received less than 500 mg/m<sup>2</sup> doxorubicin; this was 63% in patients who received more than 500 mg/m<sup>2</sup> [10]. High age and prior cardiovascular morbidity will increase these events. Nowadays, the medical treatment and the follow-up has improved considerably. One-third of the patients, however, do not recover from a reduction of LVEF after treatment with doxorubicin [13]. The reason for this irreversibility in long-term cardiac dysfunction is cell death, either by apoptosis or by necrosis [1]. These events are responsible for the increase in need for heart transplantation as definitive treatment for end-stage heart failure in long-term cancer survivors [14].

The risk for adverse cardiac events increases with the cumulative dose [15], starting from histopathologic changes at 240-250mg/m<sup>2</sup> [1], and a sharp increase of CHF from 550mg/m<sup>2</sup> [1], with 3 times increase in cardiac mortality after 20 to 30 years [16]. Remarkably, some patients who received more than 1000 mg/m<sup>2</sup>,

\*Address correspondence to this author at the Artesis-Plantijn University College, Noorderplaats 2, 2000 Antwerp, Belgium;  
Tel: 32 3 220 55 00;  
E-mail: wilhelm.mistiaen@uantwerpen.be; wilhelm.mistiaen@ap.be

however, did not develop CMP [15]. This indicates that unknown factors are involved, which could include differences in metabolism or differences in sensitivity to ROS. It is also possible that events in other cells than cardiomyocytes, present within the heart need to be investigated [16]. Moreover, age below 4 years or over 65 years, hypertension, coronary artery disease, prior mediastinal irradiation, concomitant treatment with trastuzumab or paclitaxel and genetic predisposition increases the risk for cardiotoxicity [1, 17]. The early recognized actions of doxorubicin are attributed to inhibition of synthesis of DNA and RNA by intercalation of base pair, inhibition of topo-isomerase II enzyme preventing transcription and replication of genetic information [18] and inhibition of the ligase enzyme to repair DNA, resulting in fragmentation of DNA [19]. A more recently postulated mechanism is eviction of histones [20]. The aim of this review is to describe the more recently observed cardiac specific events after administration of doxorubicin.

## METHODS

Search through Web of Science, from 2011 to 2016 resulted for the search terms (autophagy AND anthracyclines AND heart) in 5 articles. The search terms (programmed cell death AND anthracyclines AND heart / cardiac / myocard\*) led to one additional article while (apoptosis AND anthracyclines AND heart) resulted in 42 manuscripts. Secondary literature was included if historically relevant. The search was focused on the effect on cardiomyocytes *in vitro* as well as *in vivo* studies, not on arrhythmias, ischemia or pericarditis. *In vivo* as well as *in vitro* studies were included.

## RESULTS

Peculiarities of the heart, of mitochondria and of mitochondrial DNA (Table 1) are of major importance in understanding the effects of doxorubicin. The included studies showed that administration of doxorubicin results in a dose dependent reduction of the weight of the heart, with edema, disorganization of myofibrils, formation of vacuoles, lymphocytic infiltration and increase of fibroblasts and collagen, as well as LV [left ventricle] failure, with reduction of LVEF and of fractional shortening [21]. There is an effect on the cytoskeletal apparatus: 1) an impaired actin-myosin interaction [22] 2) a disruption of the formation of desmin which acts as a regulator of sarcomeres [23] resulting in a disorganization of these sarcomeres [24], and 3) a reduction of dystrophin, resulting in an

increased permeability of the sarcolemma [21]. From these studies, it becomes also evident that mitochondria are a main target of doxorubicin. Since mitochondria make up to 45% of the volume in myocardial tissues [6, 7], the heart is very vulnerable to doxorubicin. Moreover, doxorubicin concentration in mitochondria is 100 times higher compared to plasma [25, 26]. Many of these effects can be related to Reactive Oxygen Species or ROS, such as hydrogen peroxide, hydroxyl radicals and superoxide. Mitochondria are the main generators but also the targets of ROS. These organelles are involved in the signaling and buffering of calcium of the cytosol which has an importance of apoptosis. Apoptosis can be the result of mitochondrial damage [6]. Mitochondria have some peculiarities. Cardiolipin is a complex four-tail lipid structure which constitutes 20-45% of the inner mitochondrial membrane. It serves as a proton trap and as cofactor for the mitochondrial respiratory enzymes. It plays a role in the coupling of the respiratory chain and phosphorylation [6, 7, 9].

**Table 1: Peculiarities of the Heart and of Mitochondria**

The Heart
<ul style="list-style-type: none"> <li>High volume % of mitochondria [45%] with heavy reliance on oxidative phosphorylation</li> </ul>
<ul style="list-style-type: none"> <li>Low in catalase and dismutase</li> </ul>
<ul style="list-style-type: none"> <li>Small pools of ATP, which can be replenished by phosphocreatine</li> </ul>
Mitochondria
<ul style="list-style-type: none"> <li>High amount of cardiolipine in the inner membrane with high affinity for doxorubicin</li> </ul>
<ul style="list-style-type: none"> <li>Mitochondrial DNA without histone</li> </ul>
<ul style="list-style-type: none"> <li>Close proximity of mitochondrial DNA to respiratory enzymes</li> </ul>
<ul style="list-style-type: none"> <li>Lack of reparative systems for mitochondrial DNA</li> </ul>
<ul style="list-style-type: none"> <li>No histones in mitochondrial DNA with possibility to accumulate oxidative damage in comparison to nuclear DNA</li> </ul>
<ul style="list-style-type: none"> <li>Variable copies of mitochondrial DNA, depending on the cell type and developmental stage</li> </ul>

## Mechanisms and Reasons for Mitochondrial Cardiotoxicity of Doxorubicin

The classic mechanisms of doxorubicin have been explored for some time. There are several levels through which doxorubicin, given at clinical relevant dose, acts [16, 27]. These include 1) energy stress, 2) oxidative stress and 3) genotoxic stress. It should be noted that these levels show mutual interaction which complicates their representation. Moreover, some other organelles are involved. These types of stress result in

loss of cellular components and in cell death. The more important are ubiquitin proteasome proteolysis, apoptosis, autophagy, and some intermediary modes of cellular demise. These are summarized in Table 2.

**Table 2: Enzymes and Pathways Involved in Different Types of Stress**

<b>Energy Stress</b>
• Peroxisome proliferator-activated receptor-alpha [PPAR]
• Peroxisome proliferator-activated receptor receptor-gamma
• AMP-activated protein kinase [AMPK]
• Damaging creatine kinase
• Failure of the respiratory chain
<b>Oxidative Stress</b>
• NADPH oxidase [with Rac1 component as essential part]
• NADH dehydrogenase
• Histone HA2X deacetylase
• Cytochrome c reductase
• Acetylation of p53
• Endothelial nitric oxide synthase
• Extraction of iron from ferritin with subsequent complexation
• Inactivation of glutathione peroxidase
• Decrease of Cu-Zn superoxide dismutase
• Clearance of catalase by increased autophagy
• MDR1 or multi drug resistance protein-1 as efflux pump
<b>Genotoxic Stress</b>
• Inhibition of topo-isomerase II
• Inhibition of RNA polymerase
• Activation of Akt / Protein kinase B with T-cell lymphoma 1A as cofactor
• Inhibition of AMPK – related to ATP/AMP ratio
• Activation of Mitogen-activated protein kinase [MAPK]
<b>Other Organelles, with Increase in the Calcium Load of the Cytosol</b>
• Interaction with ryanodine receptors of the endoplasmatic
• Activation of the non-lysosomal protease calpain
• Stimulation of Ca/calmodulin protein kinase
<b>Apoptosis</b>
• Upregulation of the extracellular signal-regulated kinase [ERK1/2] pathway
• Activation of the pro-apoptotic c-Jun N-terminal kinase [JNK] pathway
• Inactivation of phosphatidylinositol-3-kinase [PI3/Akt or protein kinase B] pathway

- |   |
|---|
| • Inactivation of neuregulin  |
| • Downregulation of GATA4, which is responsible for the embryonic cardiac development |
| • Bcl-2, p53, Bak/Bax and cytochrome c and activation of caspase-3                    |

### Energy Stress

An increase in AMP/ATP ratio indicates a loss of ATP and is observed in an *in vitro* model [6, 27]. In case of high energy demand, the small pool of ATP in cardiomyocytes can be replenished by phospho-creatine. Creatine kinase act as modulator of the energy reservoir but this can be damaged by ROS, thereby disrupting energy homeostasis [7, 28]. As adaptation to decreased ATP output in doxorubicin-toxicity, cardiomyocytes switch over from fatty acid to glucose as substrate [7, 29, 30]. However, phosphofructokinase and the expression of peroxisome proliferator-activate receptor (PPAR)-gamma are also affected by doxorubicin. This impairs the uptake of glucose and makes matters worse [31]. The heart is less resistant to additional energy challenges in presence of growth stimulating signals. As compensation for the inability of AMP-activated protein kinase (AMPK) to fulfill its role in energy homeostasis, the creatine kinase energy buffer and transfer system has been upregulated in the acute and subacute setting [27]. In an combined in-vivo and in-vitro murine model, the effect of doxorubicin on the pathways of PPAR alpha-PGC-1alpha co-activator were investigated using PPAR inhibitors and activators. PGC-1alpha plays a role in the biogenesis of mitochondria making muscles more dependent on oxidative metabolism and less on glycolysis. In the doxorubicin group, PPAR/PGC was lower, with mitochondrial dysfunction and low ATP, and reduced mitochondrial membrane potential. Glucose and free fatty acid consumption had increased. More ROS was present, as was also apoptosis. The PPAR/PGC-1alpha pathways are involved in energy metabolism and in apoptosis in cardiomyocytes [32]. The cardiac function can acutely be impaired by the energy stress [7, 28].

### Oxidative Stress

Doxorubicin has a high affinity to cardiolipin, which is located within the inner mitochondrial membrane, and binds irreversibly to it [1, 6, 7, 33, 34]. It places doxorubicin close to the electron-transport chain, permitting formation of ROS, causing damage throughout the cytosol, the mitochondria and other subcellular components [35]. Protein oxidation is

mainly expressed as carbonyl formation in the subacute model at 6 weeks [27]. ROS persists for 5 weeks after discontinuation of doxorubicin [16]. The Rac1 component of NADPH oxidase plays an important damaging [16] role in the formation of ROS: its inhibition mitigated ROS production and hence apoptosis, while over expression of Rac1 worsened apoptosis. Inhibition of Rac1 preserves the histone H2AX deacetylase activity and prevents activation of p53. Scavenging ROS did not change the histone deacetylase H2AX activity, neither was activation of p53 altered. This indicates that Rac1 mediated cardiotoxicity involves both ROS dependent and independent pathways [36]. ROS can damage creatine kinase and contribute to the energy stress. Increase in production of ROS [6, 37] by doxorubicin occurs by utilizing NADH dehydrogenase / cytochrome c reductase and endothelial nitric oxide synthase [38] and by complexing iron, which is extracted from ferritin [21, 39-43]. Additionally, doxorubicin releases iron from its stores [9] and complexes this metal. This catalyzes hydrogen peroxide into hydroxyl radicals, adding to oxidative stress [1]. The reduction of doxorubicin, by adding one electron to the quinone moiety of the C-ring leads to formation of semiquinone which can react with molecular oxygen. By formation of superoxide, radicals can be formed by redox cycling, whereby the quinone structure has regenerated [1, 44]. This leads to the formation of ROS [45] but also to the abolishment of anti-oxidant defenses such as inactivation of GSH-1 peroxidase with a decrease of Cu-Zn superoxide dismutase [7, 40, 41]. Over expression of manganese superoxide dismutase alleviates apoptosis [1]. One molecule of doxorubicin leads to many molecules of free radicals through redox cycling! The respiratory chain starts to fail which contributes to the energy stress [46]. This generation of ROS causes peroxidation of lipids, inflammation and apoptosis [9], which is clinically relevant [16]. The clinical relevance of oxidative stress was documented in women with breast cancer: those who experienced a lowering of LVEF also had elevated levels of plasma byproducts of ROS [17]. The only other clinical article investigated the effect of BRCA 1 and 2 gene mutations on the effects of doxorubicin on the heart in breast cancer patients. Except for higher oophorectomy and early menopause, groups with and without those mutations and without mutations were comparable [47].

### **Genotoxic Stress**

Doxorubicin enters the cells through passive diffusion and bind to proteasomes [9, 48]. This complex

is translocated to the nucleus, especially in dividing cells. Doxorubicin dissociates from the proteasomes and binds to DNA by intercalation. This has a DNA adenine methyltransferase effect and results in inhibition of protein synthesis and alteration of many transcriptional factors. Nuclear proteins are displaced and chromatin aggregates. Topoisomerase II and RNA polymerase are inhibited [9]. Lesions in nuclear and mitochondrial DNA are found during the acute in-vitro experiments, resulting in apoptosis. DNA-dependent protein kinase is a crucial component in the DNA repair machinery. It signals to Akt/PKB (protein kinase B) which promotes survival after genotoxic stress. At the same time AMPK is inhibited [27]. As a response to DNA damage, p53 is activated by acetylation and the histone H2AX is phosphorylated [36]. An example of interrelation between genotoxic, energetic and oxidative stress has been observed in the effect of doxorubicin on AMPK or AMP activated protein kinase [27,36]. AMPK is activated by stress such as lowering of ATP and hence ADP/ATP ratio. ATP generating processes are activated by AMPK in order to restore the energy supply. Doxorubicin can induce “energy stress” in this respect because AMPK is paradoxically suppressed and hence the shortage of ATP remains. There was no evidence for an altered “upstream signaling” by doxorubicin which could account for this effect. Another mechanism by which AMPK is downregulated by doxorubicin might be the cross talk of AMPK with Akt/PKB (protein kinase B) and with MAPK (Mitogen-activated protein kinase). The activation of Akt pathway is a consequence of genotoxicity, while stimulation of MAPK/ERK is due to an increase in ROS [1, 27]. This contains some cytoprotective elements and could counteract apoptosis caused by genotoxicity [27]. Remarkably, defects in DNA repairing enzymes such as polymerases seem to protect against doxorubicin toxicity. On the other hand, defects in BCRA2 gene exaggerates apoptosis and CHF. Cellular DNA reparative mechanisms are of paramount importance but defects in some reparative pathways results in enhanced sensitivity to doxorubicin while other defects have a protective effect [9].

### **Effect on other Organelles than Mitochondria**

Doxorubicin also interferes with ryanodine receptors / ion channels of the sarcoplasmic reticulum which are responsible for the release of calcium ions during the excitation-contraction coupling and the buffering of cytosolic calcium [49]. Hence, the calcium homeostasis is disturbed. The cytosolic calcium content increases.

The protein folding capacity of the endoplasmic reticulum alters because the combination of increased ROS and disturbed calcium homeostasis. The accumulation of oxidative damaged and misfolded proteins leads to endoplasmic reticulum stress. Moreover, the removal of such proteins by the ubiquitin proteasome pathway could also be disturbed. Toxic aggregates contributes to myocardial dysfunction and worsens the effect of ROS [33]. Another effect of the increased load of intracellular calcium is the activation of the non-lysosomal protease calpain which might be responsible for the damage to the myofibrillar proteins, including dystrophin [21]. Doxorubicin also stimulate Ca/calmodulin protein kinase, which results in an increased leak of calcium from the sarcoplasmic reticulum [16], with an impact on contraction and relaxation of cardiomyocytes [9].

### **Modes of Loss of Cellular Components and of Cell Death**

Doxorubicin modulates p53 activity [9], which causes a series of events, including a decrease in membrane potential [6]. The mitochondrial transition pore opens [6, 7] with release of cytochrome C [1, 50] as trigger for apoptosis [25, 27, 51]. Apoptosis, of which the major steps are shown in Table 3, is also enhanced by the upregulation of the extracellular signal-regulated kinase (ERK1/2) pathway [52, 53]. Activation of the pro-apoptotic c-Jun N-terminal kinase (JNK) pathway with inactivation of the anti-apoptotic phosphatidylinositol-3-kinase (PI3/Akt or protein kinase B) pathway by daunorubicin has been observed in an in-vitro rodent model. However, JNK and Akt pathways show “cross-talk” which can complicate their actions. Anyway, activation of PI3/Akt pathway could make cells resistant to chemotherapy, while down regulation of Akt could make tumor cells more sensitive. Bcl-2 and Bcl-xL are initially upregulated after exposure to doxorubicin, but this followed by a decrease. However, treatment with anti-oxidants improves the LV function through increase in Akt, Bcl-2 and decrease of caspase activity [1]. Neuregulin, which is a pro-survival factor, plays a role herein and protects against apoptosis [1, 16]. For cardiac stem cell survival, a combination of chemotherapeutic agents may be promising [54]. However, in an acute setting – a perfused isolated heart [27], ERK as survival promoting kinase was activated and apoptosis was low, while in the subacute model in living animals with 4 weeks after last injection, the pro-apoptotic JNK was activated. Cardiomyocytes are relatively resistant to apoptosis, but when it occurs, it contributes heavily to heart

failure. Upregulation of Akt/PKB preserves viability of the cells and is cardioprotective in doxorubicin treatment [27]. Doxorubicin trigger poly (ADP-ribosyl)ation of p53, which in turn serves as a mechanism for p53 nuclear accumulation. Consistently, daunorubicin promotes increased nuclear expression of p53, without changing total cellular p53 expression. This doxorubicin -induced nuclear presence of p53 is regulated through redox-dependent mechanisms. The down regulation of GATA4 factor, which is a cardiomyocyte survival factor regulating many cardiac genes including the embryonic cardiac development, plays a role herein [16, 36, 55]. If anti-oxidant defenses are overwhelmed, the mitochondrial inner membrane permeability transitional pore opening allows an influx of cytosolic solutes, causing a mitochondrial swelling, degeneration and cardiomyocyte necrosis [9].

**Table 3: intrinsic Pathway of Apoptosis, Involving Mitochondria**

Through Damage of DNA and ROS
• Activation of p53 if DNA damage is irreparable
• Dimerization of Bak and Bax proteins (inhibited by Bcl)
• Opening of the mitochondrial permeability transition pore
• Depolarization of the mitochondrial membrane potential
• Release of cytochrome c and loss of oxidative phosphorylation
• Formation of Apaf1 (apoptotic protease activating factor 1)
• Activation of caspase 9
• Activation of caspase 3
• Condensation of chromatin, nuclear fragmentation, membrane bleb formation and rearrangement of the cytoskeleton
• Apoptosis
• Phagocytosis by polymorphonuclear cells, without inflammation

Mitochondrial fission which is formation of small rounded mitochondria, as a sign of stress, has been associated with the production of ROS and with autophagy of mitochondria, also called mitophagy [56]. An increase in autophagy flux with an increase in accumulation of autophagosomes was observed was in cultured rat cardiomyocytes. It seems that autophagy is initially upregulated as compensation for cytotoxic stress [57] by activating Bcl-2 and the autophagy related genes and recruitment of light-chain-3 [46]. But this is followed by apoptosis and necrosis after longer exposure to doxorubicin. The protein degradation machinery is downregulated leading to an accumulation of poly-ubiquitinated proteins and

autophagosomes. Aging of cardiomyocytes could accelerate and make them more susceptible for [further] exposure to doxorubicin [57]. Mitochondrial biogenesis is suppressed as a chronic consequence of exposure to doxorubicin s [58].

Autophagy, of which the major steps are shown in Table 4, acts as a double edged sword. On the one hand, it serves as a clearance and renewal mechanism and could reduce cell death, when it inhibits apoptosis. This has been observed in in-vitro as well as in-vivo murine models: production of ROS and apoptosis were mitigated by stimulation of autophagy and the morphology and function of mitochondria improved. On the other hand, inhibition of autophagy by bafilomycin-1 results in mitochondrial fission and cell death [59]. On the other hand, autophagy could lead to cell death in chronic doxorubicin toxicity, by allowing or acting synergistically with apoptosis [59-61] with ensuing loss of cardiomyocytes and cardiomyopathy. This could depend on the cell type in use [neonatal versus adult, the concentration] and the duration of treatment with doxorubicin. Inhibition of autophagy or activating protein synthesis through mTOR, Akt and ERK1/2 pathways seems to restore the expression of contractile proteins [62]. The interplay between autophagy and apoptosis is documented by the fact that in acute doxorubicin toxicity, p53 inhibits mTOR. Ablation of p53, however, is not sufficient to reduce cardiac dysfunction. The functional and structural integrity of the cardiac sarcomere requires a tight balance between protein synthesis and protein degradation by autophagy and UPP. Between both systems, a cross-talk exists [59]. It should be noted that cell death with autophagy is not the same as cell death by autophagy. But over-activation of autophagy can lead to cell death with other characteristics such as an increase in autolysosomes, typical nuclear changes and dilated endoplasmic reticulum. A new term, "autosis" has been coined [63]. Moreover, other types of cell death such as necroptosis by doxorubicin also has been observed. This is caused by damage to DNA, increase ROS production followed by depletion of ATP and cell death independent from caspase. Both apoptosis and necrosis have been observed using doxorubicin [54]. Autophagy could remove catalase which make increased autophagy responsible for increase in ROS [46, 64]. Autophagy is also sensitive to ROS, with an increase in endogenous superoxide dismutase, catalase and glutathione peroxidase. These enzymes might have an effect on autophagy [46].

**Table 4: Pathway of Macro-Autophagy**

<b>The Endoplasmatic Reticulum /Trans-Golgi -Endosomes Membrane Contribute to the Formation of a Bilayer Lipid Membrane Called Phagophore. This can Start through MAPK / Erk1/2 Signaling</b>
• Conjugation of Atg5 (autophagy gene product 5) with Atg12; Atg7 and Atg10 play a supporting role herein
• Interaction with Atg16
• Polymerization at the phagophore
• Processing of LC3 (light chain 3 protein conjugated with phosphatidyl ethanolamine) with insertion to the phagophore
• Phagophore expansion
• Engulfing target at random or selective (cytosol, organelles)
• Sequestering in autophagosome
• Maturation through fusion with lysosome
• Degradation by lysosomal enzymes

One of the few clinical – epidemiologic study investigated the difference in genome wide transcript between women who had a LVEF below versus above 40%. Especially TCL1A or T-cell lymphoma 1A (a co-activator of the Akt pro-survival factor) and an efflux pump of doxorubicin the MDR1 or multi drug resistance protein-1 were involved. Inhibition of the latter in an in-vitro experiment worsens susceptibility of the heart to doxorubicin. TCL1A reduction causes increased sensitivity to apoptosis and leads also to a reduced level of MDR1 which enhances cardiac levels of doxorubicin s [17]. The Akt pathway as well as the role of MDR1 has been established in a clinical article where breast cancer patients were treated with doxorubicin s: women who experienced a reduction of LVEF below 40% were compared with those without such changes according RNA transcripts in plasma: those with a decreased LVEF showed also a lowering for MDR1 and for a co-activator of Akt transcripts [17].

The ubiquitin proteasome pathway (UPP), of which the major steps are shown in Table 5, is activated by doxorubicin [33, 65], with an increase in 20S proteasomes, E3 ubiquitin ligases and hence increased degradation of proteins [16]. Ischemia and other cardiac disorders can damage this pathway, adding to the effects of chemotherapy [59]. The in-vivo tumor bearing murine as well as in-vitro rat cardiomyoblasts show that myofibrils become less organized after exposure to doxorubicin because of their targeting and subsequent breakdown by UPP [33]. Actin becomes disorganized and depolymerized. Absence of dystrophin increases the sensitivity of the heart to doxorubicin [16]. In lower dosage, UPP was

upregulated [33, 46, 53]. These seemingly contradictory events depend on the amount of doxorubicin molecules bound on the proteasome [48].

**Table 5: Pathway of the Ubiquitin Proteasome Proteolysis**

Tagging of the Substrate Protein by Multiple Ubiquitin Molecules by Covalent ATP Dependent Binding to the Epsilon-Amine of Lysin Residues by Ubiquitin Activating Enzyme E1
• Ubiquitin conjugating enzyme E2
• Ubiquitin ligating enzyme E3
• E3 also binds to E2
• Formation of E2-E3-substrate complex
• Recognition by specificity
• Degradation by the 26S proteasome (20S catalytic core and 19S regulator of degradation)
• Recycling of ubiquitin

### Effect of Doxorubicin on other Cells and on ECM

The undifferentiated cardiac stem cells are supposed to be more vulnerable but results seem to suggest that in differentiated cells, upregulation of oxidative phosphorylation is observed, with a compensatory increase in super oxide dismutase. The higher degree of reliance of mature cells on mitochondrial metabolism could be related to the toxicity induced by doxorubicin [8]. Nevertheless, cardiac stem cells are a target of doxorubicin [54] and a therapeutic goal is their protection. Their elimination by doxorubicin could be held responsible for long-term CHF. Shortening of telomeres and premature expression of p16 could account for senescence. Abnormalities were also observed in endothelial progenitor cells [16]. Doxorubicin activate the NFkB factor in endothelial cells, which results in apoptosis. Decreased plasma levels of endothelin-1 can be found after exposure which correlates with a decreased cardiac function. In cancer survivors, there is an increase in vascular inflammation, vascular wall stiffness and of atheromatosis. Erythropoietin derivatives restore the cardiac microvasculature and endothelial differentiation. One needs to take into account that acute effects in the laboratory differs from the mid and long-term clinical results [16].

There is a role of elevated TGF-beta in patients with heart failure; it serves to remodel the myocardium with fibrosis. Proliferation and migration of endothelial cells also reduce. Inhibition of the TGF- $\beta$  pathway alleviates

the detrimental effects of doxorubicin on endothelial cells *in vivo*. The inhibition of TGF- $\beta$  pathway seems a valid strategy for preserving and even enhancing of myocardial capillary networks and prevention of microvascular remodeling [66]. Cardiomyocytes and coronary microcirculation are tethered in a network consisting of collagen, proteoglycans, glycoproteins and glycosaminoglycans. This network is maintained and balanced by fibroblasts. It has several functions, including a scaffold for myofiber alignment, prevention overstretching of sarcomeres, transmission and coordination of forces, involvement in vasomotor reactivity in myocardial microcirculation, controlling release of cytokines. When the synthesis exceeds degradation, fibrosis is the result. In the case of the opposite, this scaffold will disrupt. Doxorubicin have acute and chronic effect on the ECM [67]. The acute effects include upregulation of matrix metalloproteinase MMP-9 (through p38/MAPK, peroxynitrite), of MMP-2 (through c-Jun N-terminal Kinase / NADPH oxidase, peroxynitrite) and of MMP-1 and MT1-MMP. ECM components such as fibronectin, tubulin, myosin-light chain kinase decrease, resulting in fibrosis and loss of cardiomyocytes, vacuolization. The actin cytoskeleton reorganizes with shrinkage and detachment of the cells by affecting the interface between these cells and the ECM. Through the loss of extracellular superoxide dismutase, endothelial cells become damaged fibroblast proliferate [68]. The chronic effects are consequences of intracellular changes of activity of NADPH oxidase and of nitric oxide synthase 2 which leads to apoptosis and fibrosis. The increase in MMP-2 persists and tissue inhibitor of MMP (TIMP-3) has reduced. The ECM preserving thrombospondin-2 is absent. This is associated to impaired Akt signaling pathway [there is a feedback loop between thrombospondin and Akt]. Cathepsins and cystatins are in close balance in healthy tissues. An increase of Cystatin C correlates with inhibition of cathepsin B and is followed by an accumulation of collagen. Chemotaxis of inflammatory cells results in a wound healing response: necrotic cells and collagen debris are removed. This degradative phase ends after one week, when TIMP are upregulated. Inflammatory cells and myofibroblasts generate TGF-beta1 which deposits collagen and inhibits matrix degeneration. This results in interstitial fibrosis, scarring and extensive cardiac ECM remodeling [69].

There is one interesting acute animal study with pregnant rats. Study of fetal and maternal cardiac

tissue showed after administration of a high dose doxorubicin unaltered fetal hearts while in maternal hearts there was obvious loss of weight, moderately reduction of LVF, with apoptosis and a decreased DNA turnover. The fetal plasma concentration of doxorubicin reached about 6% of that in the maternal circulation. Plasma BNP was lowered by doxorubicin, while in fetal circulation, BNP was higher – which could be considered as counter-regulatory and protective. It seems that fetal hearts are protected. Fetal growth restriction has been observed in clinical conditions, but this could be explained by indirect mechanisms such as maternal malnutrition and placental dysfunction [70]. These data might be useful for young women who develop a malignancy during pregnancy.

Testosterone had a protective effect against doxorubicin in rat cardiomyoblasts by counteracting senescence, which might be important for gender differences in cardiotoxicity of cancer treatment in young patients. The mechanisms involved were the androgen receptor, phosphatidylinositol-3 kinase, p53, phosphorylation of Akt and phosphorylation of nitric oxide synthase 3 [71]. These results were not confirmed by an *in vivo* adult rat model studying the effect of gender on doxorubicin toxicity: signs of cardiomyopathy and mortality were higher in male rats compared to female animals. Although oxidation levels nor the apoptosis signaling pathways were altered by doxorubicin, the level of total AMPK was decreased in male rats, together with the markers of mitochondrial biogenesis and cardiolipin content [72].

### **Cardio-Protective Measures**

Several attempts to reduce the cardiotoxicity of doxorubicin s have been developed. Only few of them proved to be clinically significant. Dexrazoxane has been used as chelator of iron [1, 4, 16, 73, 74]. Liposomal and hyaluronic acid preparations of doxorubicin s lower the delivery of the agent to the heart [1, 9, 42]. PEGylated liposomal doxorubicin showed a reduced cardiotoxic effect with less ROS and apoptosis and improved cardiac function [16, 75]. Endurance exercise also has a protective effect by inhibiting autophagy. Mitochondrial adaptations could make cells more resilient to ROS, proteolysis and apoptosis [27, 37].

Cardio-protective agents such as antioxidants, scavengers of radicals, with anti-apoptotic or anti-inflammatory properties are less convincing and

probably clinically less effective. These agents include co-enzyme Q, vitamins C and E, riboflavin, the flavonoid quercetin [76], carvacrol [34], tanshinone 2A [11, 77], arjunolic acid [78], and nutrients such as carnitine, thiamine, vitamin D, folic acid and omega-3 fatty acids [6, 38]. Melatonin has also been investigated thoroughly [7]. Vitamin E is clinically ineffective as anti-oxidant [1]. Some substances such as safranal with corcins activated mTOR, thereby inhibiting autophagy but also apoptosis with consequently preserving contractile proteins [79]. Some substances such as carnitine improved also the anti-apoptotic status, the generation of prostacyclin, promoting Akt phosphorylation and signaling [11], catalase and superoxide dismutase through PPAR alpha [38]. Docosahexaenoic acid, combined with epirubicin, on the other hand resulted in more oxidized lipids in tumor cells, but not in healthy tissues [80]. Moreover, curcumin, which is also an anti-oxidant and anti-inflammatory agent increased ROS and resulted in a depletion of glutathione during treatment with doxorubicin. This agent did not protect against apoptosis [81]. It seems that not all anti-oxidant agents have a protective effect during administration of doxorubicin s.

Tadalafil is a potent long-acting selective inhibitor of cGMP-specific phosphodiesterase-5 and has known beneficial effects on acute myocardial infarction. cGMP takes part in regulating apoptosis. Simultaneous administration of tadalafil and doxorubicin in an *in-vivo* murine model resulted functional, biochemical, and histological improvement on the heart [82]. The same observation could be made with nicorandil, which is a stimulator of cGMP formation and decreases the calcium sensitivity of smooth muscle. It activates the sarcolemma pump to remove calcium and promotes K<sup>+</sup> influx. This induces hyperpolarization and hence vasodilation. Nicorandil inhibits oxidative stress-induced myocyte apoptosis through the opening of mitochondrial K-ATP channels which can preserve mitochondrial energy production. The production of ROS has also been reduced and the ultrastructural changes have been mitigated. The ATP/ADP ratio has been preserved. The anti-tumor activity of doxorubicin remained unaltered [35]. Calcium antagonists such as amlodipine and felodipine also have beneficial effects. The latter has anti-oxidant properties which mitigates ultrastructural changes and cardiac damage [44]. Verapamil, another calcium antagonist, however, increases the susceptibility by inhibiting the multidrug resistance protein 1 MDR1 [17]. Other agents such as

angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, iron chelators, statins, and metformin are also subjected to research efforts [1, 9, 13].

These tests were mostly performed in short-term animal models or in in-vitro H9c2 rat cardiomyocytes. Although this cell line has been validated, their results and those of *in vivo* animal models are not always reproducible with humans. This might be due to the fact that this toxicity not only acts through ROS [59] but has a chronic course. In general, all anti-oxidant treatments need further research since no effect has been observed with certainty. This is also true for anti-inflammatory and anti-apoptotic substances [16]. Micro-RNA have a major role as modulators of gene expression. These small molecules have a great potential as biomarkers in this area. Overexpression of miRNA-30 protects cardiomyocytes from doxorubicin-related damage [83].

Recently, polymer nanoparticles were developed for specific deliverance of chemotherapeutic agents to cancer cells. These particles of 400-500 nm are vehicles used for delivery of hydrophobic anti-cancer drugs, like doxorubicin. Such nanoparticles can be derived from poly-lactic-co-glycolic acid (or any biodegradable polymer such as chitosan, lipids, PEG etc. ...) and quercetin (as a second, chemo-preventing agent). Modification can be obtained by coating with bovine serum albumin or histones to which chemotherapeutic agents such as doxorubicin are bound by sonication. After incubation, centrifugation and precipitation, these particles can be stored as freeze-dried or after lyophilizing. The nature of the surface of these nanoparticles is crucial to prevent clearance of these particles by the mononuclear phagocytic system. By a positive electric charge, these particles are attracted by negatively charged cancer cells. This results in a specific uptake and accumulation of these agents by the target cells. The technology has the advantage of formulating tailor-made drugs to suit the purpose of anti-cancer agents. Such nanoparticle formulation are expected to overcome multi-drug resistance by reaching and treating the target cancerous cells through their of size, charge and retention [84].

## CONCLUSIONS

The unravelling of the effects of doxorubicin s on the heart is very complex and far from complete. Even

the study of gender effects did not show unequivocal results. Most affected pathways show mutual interaction, hence there changes are difficult to interpret. Most in-vivo experiments were acute or short term. Their results do not necessarily predict events in human cardiomyocytes and are not necessarily relevant for long-term outcomes in cancer patients. These long-term events can only be examined by cardiac biopsies, which are hard to come by. Genetic variations in susceptibility need to be taken into account. Examples are the presence or absence of HER-2 mediated receptors and single-nucleotide polymorphisms for NADPH oxidase and efflux transporters. Other cells than cardiomyocytes as well as the extracellular matrix have hardly been investigated. Nevertheless, changes induced by doxorubicin s can have a major effect on cardiac function, since there is a close structural relationship between all components of the heart which affects cardiac function. Long-term animal studies are warranted. There are some important limitations: the effects of combined chemotherapeutic regimens and of prior heart disease were not included. Follow-up protocols of patients with doxorubicin -induced cardiotoxicity was also considered outside the scope of this manuscript.

## ABBREVIATIONS

<b>ADP:</b>	adenosine diphosphate
<b>AMP:</b>	adenosine monophosphate
<b>AMPK:</b>	AMP-activated protein kinase
<b>ATP:</b>	adenosine triphosphate
<b>Bc-L:</b>	b-cell lymphoma
<b>BCRA Gene:</b>	breast cancer gene
<b>BNP:</b>	B-type natriuretic peptide
<b>CHF:</b>	congestive heart failure
<b>CMP:</b>	cardiomyopathy
<b>DNA:</b>	deoxyribonucleic acid
<b>ECM:</b>	extracellular matrix
<b>GSH:</b>	glutathione
<b>JNK:</b>	c-Jun N-terminal kinase

- LV:** left ventricle / LVEF: left ventricular ejection fraction
- MAPK:** Mitogen-activated protein kinase
- MDR1:** multi drug resistance protein-1
- MMP:** matrix metalloproteinase
- mTOR:** mammalian target of rapamycin
- NADPH:** Nicotinamide adenine dinucleotide phosphate
- ROS:** reactive oxygen species
- PI3:** phosphatidylinositol-3-kinase
- PKB:** proteinkinase B
- PPAR:** peroxisomeproliferator-activate receptor
- TCL1A:** T-cell lymphoma 1A
- TGF:** transforming growth factor
- TIMP:** tissue inhibitor of MMP
- UPP:** ubiquitin proteasome pathway
- [9] Nikitovic D, Juraneck I, Wilks MF, Tzardi M, Tsatsakis A, Tzanakakis GN. Doxorubicin -Dependent Cardiotoxicity and Extracellular Matrix Remodeling. *Chest* 2014; 146: 1123-1130. <http://dx.doi.org/10.1378/chest.14-0460>
- [10] Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing doxorubicin therapy JAMA 1991; 266: 1672-1677. <http://dx.doi.org/10.1001/jama.1991.03470120074036>
- [11] Jiang B, Zhang L, Wang Y, Wu W, Li M, Guan S, *et al.* Tanshinone IIA sodium sulfonate protects against cardiotoxicity induced by doxorubicin *in vitro* and *in vivo*. *Food and Chemical Toxicology* 2009; 47: 1538-1544. <http://dx.doi.org/10.1016/j.fct.2009.03.038>
- [12] Von Hoff DD, Layard MW, Basa P. Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med* 1979; 91: 710-717. <http://dx.doi.org/10.7326/0003-4819-91-5-710>
- [13] Tan TC, Neilan TG, Francis S, Plana JC, Scherrer-Crosbie M. Doxorubicin -induced cardiomyopathy in adults. *Comprehensive Physiol* 2015; 5: 1517-1540. <http://dx.doi.org/10.1002/cphy.c140059>
- [14] Mistiaen WP. Heart transplantation in patients with previous malignancy. An overview. *Acta Cardiologica* 2015; 70: 123-130.
- [15] Jiji RS, Kramer CM, Saleno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. *J Nucl Cardiol* 2012; 19: 377-388. <http://dx.doi.org/10.1007/s12350-012-9512-2>
- [16] Lindsey ML, Lange RA, Parsons H, Andrews T, Aune GJ. The tell-tale heart: molecular and cellular responses to childhood doxorubicin exposure. *Am J Physiol Heart Circ Physiol* 2011; 307: H1379-H1389.
- [17] McCaffrey TA, Tziros C, Lewis J, Katz R, Siegel R, Weglicki W, *et al.* Genomic Profiling Reveals the Potential Role of TCL1A and MDR1 Deficiency in Chemotherapy-Induced Cardiotoxicity. *Int J Biol Sci* 2013; 9: 350-360. <http://dx.doi.org/10.7150/ijbs.6058>
- [18] Zhang S, Liu X, Bawa-Khalife T, Lu LS, Lyu YL, Liu LF *et al.* Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nature Medicine* 2012; 18: 1639-1642. <http://dx.doi.org/10.1038/nm.2919>
- [19] Osheroff. Eukaryotic Topoisomerase II: characterisation of enzyme turnover. *The Journal of Biological Chemistry* 1986; 261: 9944-9950.
- [20] Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerrckhoven R, *et al.* "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". *Nature Communications* 2013; 4: 1908. <http://dx.doi.org/10.1038/ncomms2921>
- [21] Campos EC, O'Connell JL, Malvestion LM, Dias Romano MM, Ramos SG, MRB Celes, *et al.* Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. *Eur J Pharmacol* 2011; 670: 541-553. <http://dx.doi.org/10.1016/j.ejphar.2011.09.021>
- [22] Bottone AE, Voest EE, de Beer EL. Impairment of the actin-myosin interaction in permeabilized cardiac trabeculae after chronic doxorubicin treatment. *Clin Cancer Res* 1998; 4: 1031-1037.
- [23] Sterba M, Popelová O, Lenco J, Fuciková A, Brcaková E. Proteomic insights into chronic doxorubicin cardiotoxicity. *J Mol Cell Cardiol* 2011; 7: 214-220.
- [24] Sardão VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB. Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. *Cell Biol Toxicol* 2009; 25: 227-243. <http://dx.doi.org/10.1007/s10565-008-9070-1>

## REFERENCES

- [1] Volkova M, Russell R III. Doxorubicin Cardiotoxicity: Prevalence, Pathogenesis and Treatment Current Cardiology Reviews 2011; 7: 214-220. <http://dx.doi.org/10.2174/157340311799960645>
- [2] Fujiwara A, Hoshino T, Westley J. Doxorubicin Antibiotics. *Critical Reviews in Biotechnology* 1985; 3: 133. <http://dx.doi.org/10.3109/07388558509150782>
- [3] Weiss RB. The doxorubicin s: will we ever find a better doxorubicin? *Semin Oncol* 1992; 19: 670-86. PMID 1462166.
- [4] Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol Rev* 2004; 56: 185-229. <http://dx.doi.org/10.1124/pr.56.2.6>
- [5] Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of doxorubicin chemotherapeutics: translating molecular mechanism into preventative medicine. *Mol Interv* 2005; 5: 163-71. <http://dx.doi.org/10.1124/mi.5.3.6>
- [6] Finsterer J, Ohnsorge P. Influence of mitochondrion-toxic agents on the cardiovascular system. *Regulatory Toxicol Pharmacol* 2013; 67: 434-445. <http://dx.doi.org/10.1016/j.yrtph.2013.09.002>
- [7] Govender J, Loos B, Marais A, Engelbrecht AM. Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: a review of the protective role of melatonin J Pineal Res 2014; 57: 367-380. <http://dx.doi.org/10.1111/jpi.12176>
- [8] Ana F, Branco AF, Sampaio SF, Moreira AC, Holy J, Wallace KB, *et al.* Differentiation-Dependent Doxorubicin Toxicity on H9c2 Cardiomyoblasts. *Cardiovasc Toxicol* 2012; 12: 326-340. <http://dx.doi.org/10.1007/s12012-012-9177-8>

- [25] Sokolove PM. Interactions of adriamycinaglycones with mitochondria may mediate adriamycin cardiotoxicity. *Int J Biochem* 1994; 26: 1341-1350. [http://dx.doi.org/10.1016/0020-711X\(94\)90176-7](http://dx.doi.org/10.1016/0020-711X(94)90176-7)
- [26] Tokarska-Schlattner M, Dolder M, Gerber I. Reduced creatine-stimulated respiration in doxorubicin challenged mitochondria: particular sensitivity of the heart. *Biochim Biophys Acta* 2007; 1767: 1276-1284. <http://dx.doi.org/10.1016/j.bbabi.2007.08.006>
- [27] Gratia S, Laurence K, Potenza L, Seffouh A, Novel-Chaté V, Schnebelen C, *et al.* Inhibition of AMPK signaling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative and genotoxic stress. *Cardiovasc Res* 2012; 95: 290-299. <http://dx.doi.org/10.1093/cvr/cvs134>
- [28] Ichikawa Y, Ghanefar M, Bayeva M. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. *J Clin Invest* 2014; 124: 617-630. <http://dx.doi.org/10.1172/JCI72931>
- [29] Wakasugi S, Fischman AJ, Babich JW. Myocardial substrate utilization and left ventricular function in Adriamycin cardiomyopathy. *J Nucl Med* 1993; 34: 1529-1535.
- [30] Tokarska-Schlattner M, Zaugg M, da Silva R. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. *Am J Physiol Heart Circ Physiol* 2005; 289: H37-H47. <http://dx.doi.org/10.1152/ajpheart.01057.2004>
- [31] Arunachalam S, TirupathiPichiah PB, Achiraman S. Doxorubicin treatment inhibits PPARc and may induce lipotoxicity by mimicking a type 2 diabetes-like condition in rodent models. *FEBS Lett* 2013; 587: 105-110. <http://dx.doi.org/10.1016/j.febslet.2012.11.019>
- [32] Yang Y, Zhang H, Li X, Yang T, Jiang Q. Effects of PPAR $\alpha$ /PGC-1 $\alpha$  on the energy metabolism remodeling and apoptosis in the doxorubicin induced mice cardiomyocytes *in vitro*. *Int J Clin Exp Pathol* 2015; 8: 12216-12224.
- [33] Sishi BJN, Loos B, van Rooyen B, Engelbrechts AM. Doxorubicin induces protein ubiquitination and inhibits proteasome activity during cardiotoxicity. *Toxicology* 2013; 309: 23-29. <http://dx.doi.org/10.1016/j.tox.2013.04.016>
- [34] El-Sayed EM, Mansour AM, Abdul-Hameed MS. Thymol and Carvacrol Prevent Doxorubicin-Induced Cardiotoxicity by Abrogation of Oxidative Stress, Inflammation, and Apoptosis in Rats *J Biochem Mol Toxicol* 2016; 30: 37-44. <http://dx.doi.org/10.1002/jbt.21740>
- [35] Ahmed LA, El-Maraghy. Nicorandil ameliorates mitochondrial dysfunction in doxorubicin- induced heart failure in rats: Possible mechanism of cardioprotection. *Biochemical Pharmacology* 2013; 86: 1301-1310. <http://dx.doi.org/10.1016/j.bcp.2013.07.005>
- [36] Ma J, Wang Y, Zheng D, Wei M, Wu H, Peng T. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways. *Cardiovascular Research* 2013; 97: 77-87. <http://dx.doi.org/10.1093/cvr/cvs309>
- [37] Smuder AJ, Kavazis AN, Min K, Powers SK. Doxorubicin induced markers of myocardial autophagic signaling in sedentary and exercise trained animals. *J Appl Physiol* 2013; 115: 176-185. <http://dx.doi.org/10.1152/jappphysiol.00924.2012>
- [38] Chao HH, Liu JC, Hong HJ, Lin JW, Chen CH, Cheng TH. L-carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes. *Int J Cardiol* 2011; 145: 145-152. <http://dx.doi.org/10.1016/j.ijcard.2009.06.010>
- [39] Doroshov JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. *J Clin Invest* 1980; 65: 128-135. <http://dx.doi.org/10.1172/JCI109642>
- [40] Minotti G, Cairo G, Monti E. Role of iron in doxorubicin cardiotoxicity: new tunes for an old song? *FASEB J* 1999; 13: 199-212.
- [41] Li T, Danelisen I, Singal PK. Early changes in myocardial antioxidant enzymes in rats treated with adriamycin. *Mol Cell Biochem* 2002; 232: 19-26. <http://dx.doi.org/10.1023/A:1014862912783>
- [42] Cai S, Thati S, Bagby TR, Diab HM, Davies NM, Cohen MS, *et al.* Localized doxorubicin chemotherapy with a biopolymericnanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. *J Controlled Release* 2010; 146: 212-218. <http://dx.doi.org/10.1016/j.jconrel.2010.04.006>
- [43] Ghosh J, Das J, Manna P, Sil PC. The protective role of arjunolic acid against doxorubicin induced intracellular ROS dependent JNK-p38 and p53-mediated cardiac apoptosis. *Biomaterials* 2011; 32: 4857-4866. <http://dx.doi.org/10.1016/j.biomaterials.2011.03.048>
- [44] Ghandi H, Patel VP, Mistry N, Patni N, Nandania J, Balaraman R. Doxorubicin mediated cardiotoxicity in rats: Protective role of felodipine on cardiac indices. *environmental toxicology and pharmacology* 2013; 36: 787-795.
- [45] Olson RD, Boerth RC, Gerber JG. Mechanism of Adramycin cardiotoxicity: evidence for oxidative stress. *Life Sci* 1981; 29: 1393-1401. [http://dx.doi.org/10.1016/0024-3205\(81\)90001-1](http://dx.doi.org/10.1016/0024-3205(81)90001-1)
- [46] Dickey JS, Rao VA. Current and proposed biomarkers of doxorubicin cardiotoxicity in cancer: emerging opportunities in oxidative damage and autophagy. *Curr Mol Med* 2012; 12: 763-771. <http://dx.doi.org/10.2174/156652412800792561>
- [47] Barac A, Lynce F, Smith KL, Mete M, Nawar MS *et al.* Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with doxorubicin s. *Breast Cancer Res Treat* 2016; 155: 285-293. <http://dx.doi.org/10.1007/s10549-016-3678-2>
- [48] Fekete MR, McBride WH, Pajonk F. Doxorubicin s, proteasome activity and multi-drug-resistance. *BMC Cancer* 5: 114-120. <http://dx.doi.org/10.1186/1471-2407-5-114>
- [49] Lannert JT, Georgiou DK, Joshi AD, Hamilton SL. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. <http://www.ncbi.nlm.nih.gov/pubmed/20961976> 2010; 2: a003996.
- [50] Kroemer G, Reed JC. Mitochondrial control of cell death. *Nat Med* 2000; 6: 513-519. <http://dx.doi.org/10.1038/74994>
- [51] Goormaghtigh E, Chatelain P, Caspers J. Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity. *Biochem Pharmacol* 1980; 29: 3003-3010. [http://dx.doi.org/10.1016/0006-2952\(80\)90050-7](http://dx.doi.org/10.1016/0006-2952(80)90050-7)
- [52] L'Ecuyer T, Sanjeev S, Thomas R [2006] DNA damage is an early event in doxorubicin-induced cardiac myocyte death. *Am J Physiol Heart Circ Physiol* 291: H1273-H1280. <http://dx.doi.org/10.1152/ajpheart.00738.2005>
- [53] Liu J, Mao W, Ding B. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. *Am J Physiol Heart Circ Physiol* 2008; 295: H1956-H1965. <http://dx.doi.org/10.1152/ajpheart.00407.2008>
- [54] Stulpinas A, Imbrasaitė A, Kalvelyte AV. Daunorubicin induces cell death via activation of apoptotic signalling pathway and inactivation of survival pathway in muscle-

- derived stem cells. *Cell Biol Toxicol* 2012; 28: 103-114.  
<http://dx.doi.org/10.1007/s10565-011-9210-x>
- [55] Park AM, Nagse H, Liu L, Kumar SV, Swergold N, Wong CM, *et al*. Mechanism of doxorubicin-mediated downregulation of GATA4 in the heart. *Cardiovascular Research* 2011; 90: 97-104.  
<http://dx.doi.org/10.1093/cvr/cvq361>
- [56] Rabinowitz JD, White E. Autophagy and metabolism. *Science* 2010; 330: 1344-1348.  
<http://dx.doi.org/10.1126/science.1193497>
- [57] Dimitrakis P, Romay-Ogando MI, Timolati F, Suter TM, Zuppinger C. Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes. *Cell Tissue Res* 2012; 350: 361-372.  
<http://dx.doi.org/10.1007/s00441-012-1475-8>
- [58] Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, Shah AM, *et al*. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. *Cancer Res* 2010; 70: 9287-9297.  
<http://dx.doi.org/10.1158/0008-5472.CAN-10-2664>
- [59] Sishi BJN, Loos B, van Rooyen B, Engelbrechts AM. Autophagy upregulation promotes survival and attenuates doxorubicin-induced Cardiotoxicity. <http://dx.doi.org/10.1016/j.bcp.2012.10.005>
- [60] de Meyer GR, Martinet W. Autophagy in the cardiovascular system. *Biochim Biophys Acta* 2009; 1793: 1485-1495.  
<http://dx.doi.org/10.1016/j.bbamcr.2008.12.011>
- [61] Gustafsson AB, Gottlieb RA. Autophagy in ischemic heart disease. *Circ Res* 2009; 104: 150-158.  
<http://dx.doi.org/10.1161/CIRCRESAHA.108.187427>
- [62] Chahine N, Nader M, Duc L, Martiny L, Chahine R. Saffron extracts alleviate cardiomyocytes injury induced by doxorubicin and ischemia-reperfusion *in vitro*. *Drug Chemical Toxicol* 2016; 39: 87-96.  
<http://dx.doi.org/10.3109/01480545.2015.1036281>
- [63] Liu Y, Shoji-Kawata S, Sumpter RM Jr. Autophagy is a Na<sup>+</sup>, K<sup>+</sup>-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. *Proc Natl Acad Sci USA* 2013; 110: 20364-20371.  
<http://dx.doi.org/10.1073/pnas.1319661110>
- [64] Yu L, Wan F, Dutta S, Welsh S, Liu Z, Freundt E, *et al*. Autophagic programmed cell death by selective catalase degradation. *Proc Natl Acad Sci USA* 2006; 103: 4952-4957.  
<http://dx.doi.org/10.1073/pnas.0511288103>
- [65] Kumarapeli AR, Horak KM, Glasford JW, Li J, Chen Q, Zheng H, *et al*. A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. *FASEB J* 2005; 19: 2051-2053.  
<http://dx.doi.org/10.1096/fj.05-3973fje>
- [66] Sun Z, Schriever J, Tang M, Marlin J, Taylor F, Shohet RV, *et al*. The TGF- $\beta$  pathway mediates doxorubicin effects on cardiac endothelial cells. *Journal of Molecular and Cellular Cardiology* 2016; 90: 129-138.  
<http://dx.doi.org/10.1016/j.yjmcc.2015.12.010>
- [67] Robinson TF, Geraci MA, Sonnenblick EH, Factor SM. Coiled perimysial fibers of papillary muscle in rat heart: morphology, distribution, and changes in configuration. *Circ Res* 1988; 63: 577-592.  
<http://dx.doi.org/10.1161/01.RES.63.3.577>
- [68] Ivanova M, Dovinova I, Okruhlicova L, Tribulová N, Šimončíková P, Baertekova M, *et al*. Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats. *Acta Pharmacol Sin* 2012; 33: 459-469.  
<http://dx.doi.org/10.1038/aps.2011.194>
- [69] van Almen GC, Swinnen M, Carai P, Verhesen W, Cleutjens JPM. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. *J Mol Cell Cardiol* 2011; 51(3): 318-328.  
<http://dx.doi.org/10.1016/j.yjmcc.2011.05.010>
- [70] Gziri MM, Pokreisz P, De Vos R, Verbeken E, Debiève F, Mertens L, *et al*. Fetal rat hearts do not display acute cardiotoxicity in response to maternal doxorubicin treatment. *J Pharmacol Exp Therap* 2013; 346: 362-369.  
<http://dx.doi.org/10.1124/jpet.113.205419>
- [71] Altieri P, Barisione C, Lazzarini E, Garuti A, Bezante GP, Canepa M, *et al*. Testosterone Antagonizes Doxorubicin-Induced Senescence of Cardiomyocytes. *J Am Heart Assoc* 2016; 5: e002383 doi: 10.1161/JAHA.115.002383.  
<http://dx.doi.org/10.1161/JAHA.115.002383>
- [72] Moulin M, Piquereau J, Mateo P, Fortin D, Rucker-Martin C, Gressette M, *et al*. Sexual Dimorphism of Doxorubicin-Mediated Cardiotoxicity Potential Role of Energy Metabolism Remodeling. *Circ Heart Fail* 2015; 8: 98-108.  
<http://dx.doi.org/10.1161/CIRCHEARTFAILURE.114.001180>
- [73] van Dalen EC, Caron HN, Dickinson HO, Kremer LC, Van Dalen, Elvira C, ed. Cardioprotective interventions for cancer patients receiving doxorubicin s. *Cochrane Database Syst Rev* 2008:  
<http://dx.doi.org/10.1002/14651858.CD003917.pub3>
- [74] Hong JH, Liu JC, Chen PY, Chen JJ, Chan P, Cheng TH. Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway. *Int J Cardiol* 2012; 157: 174-179.  
<http://dx.doi.org/10.1016/j.ijcard.2010.12.012>
- [75] Toldo S, Goehe RW, Lotrionte M, Mezzaroma E, Sumner ET, Biondi-Zoccai GGL, *et al*. Comparative Cardiac Toxicity of Doxorubicin s *In vitro* and *In vivo* in the Mouse. *PLOS one* 2013; 8(3): e58421.  
<http://dx.doi.org/10.1371/journal.pone.0058421>
- [76] Matouk AI, Taye A, Heeba G, El-Moselhy MA. Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats. *Environmental toxicology and pharmacology* 2013; 36: 443450.  
<http://dx.doi.org/10.1016/j.etap.2013.05.006>
- [77] Gao J, Yang GQ, Pi RB, Li RF, Wang P, Zhang H, *et al*. Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. *Translational Research* 2008; 151: 79-87.  
<http://dx.doi.org/10.1016/j.trsl.2007.11.005>
- [78] Ghosh J, Das J, Manna P, Sil PC. The protective role of arjunolic acid against doxorubicin induced intracellular ROS dependent JNK-p38 and p53-mediated cardiac apoptosis. *Biomaterials* 2011; 32: 4857-4866.  
<http://dx.doi.org/10.1016/j.biomaterials.2011.03.048>
- [79] Chahine N, Nader M, Duc L, Martiny L, Chahine R. Saffron extracts alleviate cardiomyocytes injury induced by doxorubicin and ischemia-reperfusion *in vitro*. *Drug Chemical Toxicol* 2016; 39: 87-96.  
<http://dx.doi.org/10.3109/01480545.2015.1036281>
- [80] Hajjaji N, Besson P, Bougnoux P. Tumor and non-tumor tissues differential oxidative stress response to supplemental DHA and chemotherapy in rats. *Cancer Chemother Pharmacol* 2012; 70: 17-23.  
<http://dx.doi.org/10.1007/s00280-012-1884-0>
- [81] Hosseinzadeh L, Behravan J, Mosaffa F, Bahrami G, Bahrami A, Karimi G. Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. *Food and Chemical Toxicology* 2011; 49: 1102-1109.  
<http://dx.doi.org/10.1016/j.fct.2011.01.021>
- [82] Jin Z, Zhang J, Zhi H, Hong B, Zhang S, *et al*. The beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. *J Cardiol* 2013; 62: 110-116.  
<http://dx.doi.org/10.1016/j.jicc.2013.03.018>

- [83] Roca-Alonso L, Pellegrino L, Castellano L, Stebbing J. Breast Cancer Treatment and Adverse Cardiac Events: What Are the Molecular Mechanisms? *Cardiology* 2012; 122: 253-259.  
<http://dx.doi.org/10.1159/000339858>
- [84] Saha C, Kaushik A, Das A, Pal, S, Majumder D. Anthracycline Drugs on Modified Surface of Quercetin-Loaded Polymer Nanoparticles: A Dual Drug Delivery Model for Cancer Treatment. *Plos one* 2016; 11(5): e0155710  
<http://dx.doi.org/10.1371/journal.pone.0155710>

---

Received on 21-08-2015

Accepted on 01-09-2016

Published on 28-09-2016

<http://dx.doi.org/10.15379/2410-2822.2016.03.02.01>

© 2016 Wilhelm P Mistiaen; Licensee Cosmos Scholars Publishing House.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License

(<http://creativecommons.org/licenses/by-nc/3.0/>), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.